文献速递前列腺癌

一线雄激素受体通路抑制剂对初诊转移性去势敏感性前列腺癌的生存获益

Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-07-25

该研究基于美国退伍军人事务部384例初诊mCSPC患者真实世界数据,比较ADT单药、ADT+第一代非甾体抗雄激素(NSAA)与ADT+雄激素受体通路抑制剂(ARPI)的结局。结果显示ADT+ARPI较ADT单药显著改善总生存、降低进展至mCRPC风险并提高PSA缓解率,而ADT+NSAA与ADT单药无差异。

要点

  • ADT+ARPI较ADT单药显著改善初诊mCSPC患者总生存(HR 0.61)。
  • ADT+ARPI显著降低进展至mCRPC风险(HR 0.46)并提高PSA缓解率。
  • ADT+NSAA的结局与ADT单药无差异。

核心结论

  • 在初诊mCSPC患者中,一线ADT+ARPI较ADT单药与显著改善的结局相关。
  • 真实世界结果与临床试验显示的获益一致,支持将ARPI治疗强化整合入临床实践。

研究设计与样本

  • 研究纳入美国退伍军人事务部2018年2月至2020年6月初诊mCSPC患者,经病历审查确认。
  • 按预设招募配额分为ADT单药组163例、ADT+NSAA组101例、ADT+ARPI组120例,共384例。
  • 结局包括IPTW调整的总生存、进展至mCRPC及PSA缓解。

主要发现

  • ADT单药、ADT+NSAA、ADT+ARPI组中位随访分别为37.2、38.1、34.8个月。
  • ADT+ARPI较ADT单药总生存显著更优(HR 0.61,95%CI 0.43–0.87,p=0.007)。
  • ADT+ARPI较ADT单药进展至mCRPC风险更低(HR 0.46,95%CI 0.33–0.66,p<0.001)。
  • ADT+ARPI较ADT单药PSA缓解率更高(PSA较基线下降≥50%和≥90%、一线治疗期间任意时间PSA<0.2 ng/mL和<0.1 ng/mL,均p<0.05)。
  • ADT+NSAA的结局与ADT单药无差异。

关键数值与推荐

  • ADT+ARPI较ADT单药总生存HR 0.61(95%CI 0.43–0.87,p=0.007)。
  • ADT+ARPI较ADT单药进展至mCRPC的HR 0.46(95%CI 0.33–0.66,p<0.001)。
  • ADT+ARPI组PSA缓解率各项指标均优于ADT单药(p<0.05)。

临床怎么用

  • 对初诊mCSPC患者,可考虑一线ADT联合ARPI以改善生存和疾病控制。
  • ADT+ARPI是该研究中最常见的mCSPC二线治疗和mCRPC一线治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited real-world data exist on the effectiveness of treatment intensification (TI) with androgen receptor pathway inhibitors (ARPI) in de novo metastatic castration-sensitive prostate cancer (mCSPC). This study compared outcomes of TI or first-generation nonsteroidal antiandrogens (NSAAs) to androgen-deprivation therapy (ADT) alone in US patients with de novo mCSPC. METHODS: Veterans Affairs patients with de novo mCSPC (February 2018-June 2020) confirmed via chart review were grouped into ADT alone, ADT + NSAAs, or ADT + ARPI cohorts using predefined recruitment quotas. Outcomes included inverse probability of treatment weighting (IPTW)-adjusted overall survival (OS), progression to metastatic castration-resistant prostate cancer (mCRPC), and prostate-specific antigen (PSA) response. RESULTS: A total of 384 patients were identified (ADT alone: 163, ADT + NSAA: 101, ADT + ARPI: 120). Median follow-up was 37.2, 38.1, and 34.8 months for ADT alone, ADT + NSAA, and ADT + ARPI, respectively. Compared with ADT alone, ADT + ARPI showed significantly better OS (HR [95% CI]: 0.61 [0.43 to 0.87], p = 0.007), lower risk of progression to mCRPC (0.46 [0.33 to 0.66], p < 0.001), and higher PSA response rate (PSA decline of ≥50% and ≥90% from baseline, and to <0.2 ng/mL and <0.1 ng/mL any time during first-line treatment; all p < 0.05). Outcomes with ADT + NSAA did not differ from ADT alone. ADT + ARPI was the most common second-line mCSPC and first-line mCRPC treatment. CONCLUSIONS: First-line ADT + ARPI was associated with significantly improved outcomes vs ADT alone in de novo mCSPC. These real-world results align with the benefits demonstrated in trials, supporting integration of TI with ARPIs into clinical practice to improve survival outcomes in patients with de novo mCSPC.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Freedland SJ, Hong A, El-Chaar N, et al. Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2025. PMID: 40707817. doi:10.1038/s41391-025-01000-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。